Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Sales and Divestitures: 2023-2025

Historic Gains from Sales and Divestitures for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Sep 2025 value amounting to $215,795.

  • Harmony Biosciences Holdings' Gains from Sales and Divestitures rose 59.85% to $215,795 in Q3 2025 from the same period last year, while for Sep 2025 it was $215,795, marking a year-over-year increase of 59.85%. This contributed to the annual value of $135,000 for FY2024, which is 350.00% up from last year.
  • Harmony Biosciences Holdings' Gains from Sales and Divestitures amounted to $215,795 in Q3 2025, which was up 26.35% from $170,795 recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Gains from Sales and Divestitures ranged from a high of $215,795 in Q3 2025 and a low of $15,000 during Q1 2024.
  • Over the past 3 years, Harmony Biosciences Holdings' median Gains from Sales and Divestitures value was $30,000 (recorded in 2023), while the average stood at $84,374.
  • In the last 5 years, Harmony Biosciences Holdings' Gains from Sales and Divestitures slumped by 50.00% in 2024 and then soared by 1,038.63% in 2025.
  • Harmony Biosciences Holdings' Gains from Sales and Divestitures (Quarterly) stood at $30,000 in 2023, then soared by 350.00% to $135,000 in 2024, then soared by 59.85% to $215,795 in 2025.
  • Its Gains from Sales and Divestitures stands at $215,795 for Q3 2025, versus $170,795 for Q2 2025 and $121,521 for Q1 2025.